Deregulation of protein phosphatase 2A inhibitor SET is associated with malignant progression in breast cancer
Katsunori Tozuka(Saitama Cancer Center), Masami Suganuma(Saitama University), Pattama Wongsirisin(Saitama Cancer Center), Miki Kanno(Saitama Cancer Center), Kenichi Inoue(Universitair Ziekenhuis Leuven), Hiroshi Matsumoto, Ken Takai(University of California, San Francisco), Shigenori E. Nagai(Saitama Cancer Center), Kazuyuki Kubo(Saitama Cancer Center), Yasuhito Kobayashi(Saitama Prefecture), Yoshihito Shimizu(Saitama Prefecture)
Cited by 5
Related Papers
MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy
|Journal of Clinical Oncology|2017|1.7k
The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2
|JAMA Oncology|2019|1k
Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells
|Nature|2015|925
Liver tumor promotion by the cyanobacterial cyclic peptide toxin microcystin-LR
|Journal of Cancer Research and Clinical Oncology|1992|807
Okadaic acid: an additional non-phorbol-12-tetradecanoate-13-acetate-type tumor promoter.
|Proceedings of the National Academy of Sciences|1988|602